8-K current report · filed Oct 21, 2026

Voyager Therapeutics, Inc. (VYGR) 8-K Current Report: October 21, 2026

Item 5.02VYGR overview

Short answer

Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Robin Swartz appointed President effective October 20, 2026, strengthening internal succession continuity.

Voyager Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Robin Swartz appointed President effective October 20, 2026, strengthening internal succession continuity
  • Expected CEO transition after first-quarter 2027 VY1706 acute safety data, with Alfred Sandrock remaining on the Board
  • Annual salary $625,000, target cash bonus 50% of base salary
  • Equity award: option for 318,500 shares plus restricted stock units for 68,250 shares
  • Change-in-control severance includes 12 months’ salary, pro rata bonus, COBRA coverage and full equity acceleration

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Voyager Therapeutics, Inc. 8-K filings

Get the next VYGR 8-K as it lands

Follow VYGR for push alerts, or ask the research agent what this filing means.